CLC bio

CLC bio was a Danish bioinformatics software company established in Aarhus and commercially active from January 1, 2005. The company developed software for analyzing biological data, serving researchers and organizations in academic institutions, biotechnology, and related life-science fields. Its products were designed to make complex computational biology workflows accessible through graphical user interfaces as well as command-line, application-programming, and enterprise-oriented tools. The company’s core platform supported work across genomics, transcriptomics, epigenomics, proteomics-related applications, structural biology, and microbial research. Capabilities included high-throughput sequencing read mapping, de novo assembly, variant and structural-variation detection, RNA sequencing analysis, ChIP-seq, small-RNA analysis, genome finishing, pathway analysis, and visualization and comparison of biological datasets. CLC bio also developed proprietary algorithms and accelerated implementations of established methods, including work using SIMD techniques and, in its earlier hardware activities, field-programmable gate arrays. A notable aspect of the company’s product strategy was the combination of specialist bioinformatics functionality with a visual workflow environment. Around 2010, CLC bio was described as an early commercial bioinformatics platform to provide a graphical system for constructing, managing, and deploying analysis workflows. Its software portfolio was available for desktop operating systems including Mac OS X, Windows, and Linux, and was later organized into themed Workbenches and plugins focused on areas such as genomics and pathway analysis. The platform also exposed command-line tools, SOAP and REST interfaces, and subsequently supported containerized tools. CLC bio expanded beyond Denmark during the late 2000s and early 2010s. By 2012 it had offices or operations in Cambridge, Massachusetts; Tokyo; Taipei; and Delhi. Its workforce had a strong research orientation, with a significant proportion holding doctoral degrees, and the company reported a user community of approximately 250,000 people across academic and biotechnology settings. Product development was partly supported through collaboration with researchers working on grant-funded projects. QIAGEN acquired CLC bio in 2013. The acquisition brought CLC bio’s software and bioinformatics capabilities into QIAGEN’s portfolio. In 2014, CLC bio was merged into QIAGEN’s bioinformatics research and development organization alongside other acquired platforms. The CLC bio corporate entity therefore no longer operated as an independent company, although CLC-branded technologies and successor products continued within QIAGEN’s bioinformatics activities. Later platform developments associated with the CLC technology included cloud-based workflow execution through the CLC Genomics Cloud Engine, launched in 2017 for Amazon Web Services, followed by AWS GovCloud support in 2019 and desktop-to-cloud workflow execution from CLC Genomics Workbench in 2020.

CLC bio began commercial activities in Aarhus, Denmark, on January 1, 2005. Its business was centered on software for bioinformatics and computational analysis of biological data. Product development was supported not only by conventional commercial work but also by collaborations with researchers involved in grant-funded projects. This helped connect the company’s engineering efforts with practical requirements in academic and biotechnology research. The company developed a multi-environment software portfolio for Mac OS X, Windows, and Linux desktops, as well as enterprise and later cloud deployments. Its platform addressed a wide range of biological analysis tasks, including sequencing-data processing, read mapping, de novo assembly, variant discovery, structural-variation analysis, RNA-Seq, ChIP-seq, small-RNA analysis, genome finishing, microbial genomics, pathway analysis, and visualization of genomic, transcriptomic, and epigenomic information. As the portfolio expanded, functionality was organized into specialized Workbenches and plugins serving different research domains. CLC bio’s differentiation lay partly in the effort to make advanced computational workflows usable through a visual interface. Around 2010, it was recognized as an early commercial bioinformatics platform offering a graphical environment for assembling, managing, and deploying workflows. The company also provided command-line tools, SOAP and REST APIs, and later support for containerized tools. Alongside its own algorithms, CLC bio produced accelerated implementations of established methods, including SIMD-based software and earlier FPGA-oriented high-performance computing solutions for algorithms such as HMMER, Smith-Waterman, and ClustalW. The hardware-focused products were subsequently discontinued. By 2012, CLC bio had expanded its international presence with offices in Cambridge, Massachusetts, Tokyo, Taipei, and Delhi. Its employees were substantially drawn from research backgrounds, and the company reported that roughly 30 percent of its staff held PhDs. At that time, its user base was estimated at about 250,000 people across academic institutions and biotechnology companies, indicating that the platform had moved beyond a narrow specialist niche. QIAGEN acquired CLC bio in 2013. The transaction ended CLC bio’s independent corporate development and brought its software into QIAGEN’s bioinformatics portfolio. In 2014, CLC bio was merged into QIAGEN’s bioinformatics research and development division along with several other acquired platforms. The CLC technology subsequently continued through QIAGEN-associated products and development activities. Cloud computing became a later phase of the platform’s evolution. In 2017, the CLC Genomics Cloud Engine was introduced as a command-line-driven service for running bioinformatics workflows on Amazon Web Services. The service was adapted for AWS GovCloud in 2019. In 2020, a free plug-in enabled execution on AWS directly from the desktop CLC Genomics Workbench. These developments extended the original desktop and enterprise workflow model toward scalable cloud execution, while preserving the platform’s emphasis on reproducible, configurable analysis pipelines.

• 2020

  AWS plug-in released for CLC Genomics Workbench

  [1]CLC bioen.wikipedia.org

  A free plug-in allowed desktop Workbench users to execute workflows on AWS.

• 2019

  AWS GovCloud support added

  [1]CLC bioen.wikipedia.org

  The cloud platform was adapted for and approved for use in AWS GovCloud.

• 2017

  CLC Genomics Cloud Engine launched

  [1]CLC bioen.wikipedia.org

  CLC bio introduced a cloud platform for command-line execution of bioinformatics workflows on Amazon Web Services.

• 2014

  Merged into QIAGEN’s bioinformatics research and development division

  [1]CLC bioen.wikipedia.org

  CLC bio was combined with other acquired platforms within QIAGEN’s bioinformatics research and development organization.

• 2013

  Acquired by QIAGEN

  [1]CLC bioen.wikipedia.org

  QIAGEN acquired CLC bio and incorporated its bioinformatics capabilities into the QIAGEN portfolio.

• 2012

  International office network and user base established

  [1]CLC bioen.wikipedia.org

  The company had additional offices in Cambridge, Tokyo, Taipei, and Delhi and a reported user base of approximately 250,000 across academic and biotechnology organizations.

• 2010

  Graphical workflow platform becomes a defining capability

  [1]CLC bioen.wikipedia.org

  CLC bio’s commercial platform provided a graphical environment for building, managing, and deploying bioinformatics workflows, alongside command-line and API access.

• 2005

  Commercial activities begin in Aarhus

  [1]CLC bioen.wikipedia.org

  CLC bio began commercial operations in Aarhus, Denmark, focusing on software for biological data analysis.

Research-oriented bioinformatics software combining broad biological data-analysis capabilities with accessible visual workflows, command-line access, programmable interfaces, and scalable enterprise or cloud execution.

• Desktop bioinformatics software

  CLC Genomics Workbench

  CLC Genomics Workbench was the company’s principal desktop-oriented environment for biological data analysis. It provided a graphical interface for constructing and running workflows and supported research tasks such as sequence-data processing, read mapping, de novo assembly, variant analysis, RNA-Seq, microbial genomics, and visualization. The environment was designed to make complex analyses accessible to researchers while retaining command-line and extensibility options. A later AWS plug-in connected the desktop workflow experience to cloud execution.

• Bioinformatics application modules

  CLC Workbenches and plugins

  As CLC bio expanded its software capabilities, the platform was divided into themed Workbenches and plugins. These modules grouped tools for areas including genomics, pathway analysis, and other omics disciplines. Functionality covered sequencing analysis, genome finishing, structural-variation detection, transcriptomic and epigenomic analysis, microbial research, structural biology, and comparative visualization.

• Cloud bioinformatics platform · 2017

  CLC Genomics Cloud Engine

  The CLC Genomics Cloud Engine was a command-line-driven platform for executing bioinformatics workflows on Amazon Web Services. It extended CLC bio’s workflow model from local and enterprise computing into cloud infrastructure. The platform later supported AWS GovCloud, and desktop users could access AWS execution through a plug-in for CLC Genomics Workbench.

• Bioinformatics acceleration hardware

  FPGA-based high-performance computing solutions

  CLC bio initially presented high-performance computing solutions using FPGA technology to accelerate computational biology algorithms, including HMMER, Smith-Waterman, and ClustalW implementations. These hardware-oriented products complemented the company’s software research but were later no longer developed.

• 2017

  Launch of CLC Genomics Cloud EngineProduct launch

  Background

  Demand for scalable cloud infrastructure created an opportunity to extend CLC bio’s workflow software beyond desktop and enterprise deployments.

  Action taken

  CLC bio launched a command-line-driven service for running bioinformatics workflows on Amazon Web Services.

  Aftermath

  The platform later gained AWS GovCloud support and desktop integration through a CLC Genomics Workbench plug-in.

  Source

• 2013

  QIAGEN acquisitionM&A

  Background

  CLC bio had developed a substantial bioinformatics software portfolio and international user base serving academic and biotechnology researchers.

  Action taken

  QIAGEN acquired CLC bio and incorporated its software and capabilities into its broader life-science technology portfolio.

  Aftermath

  CLC bio ceased operating as an independent company and its activities were subsequently integrated into QIAGEN’s bioinformatics research and development organization.

  Source

1. 1CLC bioen.wikipedia.org